CORONA Remedies reported strong financial performance for the second quarter and first half of FY26, posting double-digit growth across revenue and profits, supported by steady execution and robust traction in its core therapeutic segments.
For the quarter ended September 30, 2025, the company recorded consolidated revenue from operations of ₹361.13 crore, while revenue for the first half of FY26 reached ₹707.67 crore. This marked year-on-year growth of 15.1 per cent for Q2 and 17 per cent for H1, significantly outpacing the overall Indian Pharmaceutical Market.
Profitability improved at a faster pace than revenue. Profit after tax rose to ₹52.32 crore in Q2 FY26, reflecting a 21.8 per cent increase over the same period last year. For the half year, PAT climbed to ₹98.52 crore, registering a sharp 35.1 per cent year-on-year growth.
During H1 FY26, CORONA Remedies reported a gross profit of ₹573.24 crore and EBITDA of ₹148.25 crore, with an EBITDA margin of 20.9 per cent. The company maintained strong return metrics, with return on equity at 31.1 per cent and return on capital employed at 49.7 per cent. Operating cash flow remained healthy at 76.5 per cent of EBITDA, while net working capital days stood at 23.
The company attributed the performance to continued investments in strengthening its field force, expanding its brand portfolio, and increasing penetration in specialist-driven prescriptions. CORONA Remedies also acknowledged the support of its banking partners during its successful stock market listing and highlighted the contribution of employees and stakeholders in sustaining growth momentum.
